A Phase II Study of Docetaxel in Patients with Relapsed and Refractory Ewing's Tumours

T.  Meyer; A.  Mctiernan; J.  Whelan

doi:10.1080/1357714031000114192

Sarcoma (Jan 2003)

A Phase II Study of Docetaxel in Patients with Relapsed and Refractory Ewing's Tumours

T. Meyer,
A. Mctiernan,
J. Whelan

Affiliations

T. Meyer: The London Bone and Soft Tissue Tumour Service, The Meyerstein Institute of Oncology, University College London Hospitals, London W1N 8AA, UK
A. Mctiernan: The London Bone and Soft Tissue Tumour Service, The Meyerstein Institute of Oncology, University College London Hospitals, London W1N 8AA, UK
J. Whelan: The London Bone and Soft Tissue Tumour Service, The Meyerstein Institute of Oncology, University College London Hospitals, London W1N 8AA, UK

DOI: https://doi.org/10.1080/1357714031000114192
Journal volume & issue: Vol. 7, no. 1
pp. 13 – 17

Abstract

Read online

Purpose. The prognosis for patients with Ewing's tumours who have metastases at presentation or who are refractory to standard chemotherapy regimens remains poor. There is therefore a need to evaluate the role of new agents. This report describes the initial results of a prospective phase II trial of docetaxel in patients with progressive or refractory Ewing's tumours.

Published in Sarcoma

ISSN: 1357-714X (Print); 1369-1643 (Online)
Publisher: Hindawi Limited
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://onlinelibrary.wiley.com/journal/5805

About the journal